3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Metastatic Castration Resistant Prostate Cancer
1
Interventions
Carboplatin
27
pembrolizumab
26
Cisplatin
24
Paclitaxel
21
Nivolumab
19
Gemcitabine
16
Pemetrexed
14
Rituximab
14
Ipilimumab
12
Cyclophosphamide
11
Dexamethasone
11
Fluorouracil
10
Capecitabine
9
Docetaxel
9
durvalumab
9
trastuzumab deruxtecan
9
Lenalidomide
8
Oxaliplatin
8
atezolizumab
8
Doxorubicin
7
daratumumab
7
osimertinib
7
Bortezomib
6
Cytarabine
6
Leucovorin
6
Trastuzumab
6
olaparib
6
venetoclax
6
130-nm albumin-bound paclitaxel
5
Ado-Trastuzumab Emtansine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
rucaparib
×
1 year
×
Clear all
NCT02975934
2025-07-25
TRITON3
pharmaand GmbH
Phase 3
Completed
405 enrolled
34 charts
1 FDA